USD 9.46
(-0.11%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 291 Thousand CAD | 0.0% |
2022 | - CAD | 0.0% |
2021 | - CAD | 0.0% |
2020 | - CAD | 0.0% |
2019 | - CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 212 Thousand CAD | -27.15% |
2023 Q3 | 366 Thousand CAD | 0.0% |
2023 FY | 291 Thousand CAD | 0.0% |
2023 Q1 | - CAD | 0.0% |
2023 Q4 | 291 Thousand CAD | -20.49% |
2023 Q2 | - CAD | 0.0% |
2022 Q2 | - CAD | 0.0% |
2022 FY | - CAD | 0.0% |
2022 Q4 | - CAD | 0.0% |
2022 Q3 | - CAD | 0.0% |
2022 Q1 | - CAD | 0.0% |
2021 Q1 | - CAD | 0.0% |
2021 FY | - CAD | 0.0% |
2021 Q4 | - CAD | 0.0% |
2021 Q3 | - CAD | 0.0% |
2021 Q2 | - CAD | 0.0% |
2020 FY | - CAD | 0.0% |
2020 Q3 | 107.41 Thousand CAD | 0.0% |
2020 Q2 | - CAD | 0.0% |
2020 Q1 | - CAD | 0.0% |
2020 Q4 | - CAD | -100.0% |
2019 FY | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
AIM ImmunoTech Inc. | 495 Thousand USD | 41.212% |
Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -6.204% |
Armata Pharmaceuticals, Inc. | 120.37 Million USD | 99.758% |
Actinium Pharmaceuticals, Inc. | 2.11 Million USD | 86.228% |
Azitra, Inc. | 885.94 Thousand USD | 67.154% |
Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -627.518% |
Chromocell Therapeutics Corporation | 1.26 Million USD | 77.063% |
Calidi Biotherapeutics, Inc. | 7.23 Million USD | 95.978% |
CEL-SCI Corporation | 13.57 Million USD | 97.856% |
iBio, Inc. | 4.46 Million USD | 93.475% |
Lineage Cell Therapeutics, Inc. | 2.95 Million USD | 90.142% |
MAIA Biotechnology, Inc. | - USD | -Infinity% |
Matinas BioPharma Holdings, Inc. | 3.55 Million USD | 91.817% |
Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | 88.046% |
NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | 89.38% |
NanoViricides, Inc. | - USD | -Infinity% |
Oragenics, Inc. | 312.7 Thousand USD | 6.94% |
BiomX Inc. | 15.09 Million USD | 98.072% |
BiomX Inc. | 15.09 Million USD | 98.072% |
Protalix BioTherapeutics, Inc. | 26.28 Million USD | 98.893% |
Palatin Technologies, Inc. | 590.33 Thousand USD | 50.706% |
Scorpius Holdings, Inc. | 14.04 Million USD | 97.928% |